Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

simtuzumab

- PMLiVE

Gilead’s Trodelvy plus Keytruda shows positive results in metastatic breast cancer

The combination treatment showed a 35% reduction in the risk of disease progression

- PMLiVE

Gilead appoints Keeley Wettan as Executive VP, General Counsel, Legal & Compliance

Wettan has served at Gilead for over 14 years

- PMLiVE

Gilead agrees on affordable medicines plan with US government

The company recently announced a $32bn investment in US R&D and manufacturing

- PMLiVE

Gilead’s Yescarta shows benefits for patients with large B-cell lymphoma

This is the most common type of non-Hodgkin lymphoma worldwide

- PMLiVE

Gilead reports Trodelvy breast cancer trial missed primary survival endpoint

The drug treatment is being evaluated in several ongoing phase 3 trials

- PMLiVE

Mainz Biomed reports on blood-based screening test for pancreatic cancer

The study demonstrated strong clinical accuracy in differentiating pancreatic cancer patients from control subjects

- PMLiVE

Gilead shares promising phase 3 results for Trodelvy plus Keytruda in aggressive breast cancer

Triple-negative breast cancer accounts for approximately 15% of all cases of the disease

- PMLiVE

Gilead’s seladelpar recommended by CHMP to treat primary biliary cholangitis

The rare liver disease affects approximately 15 per 100,000 people in Europe

- PMLiVE

Gilead’s Livdelzi receives FDA accelerated approval to treat primary biliary cholangitis

The company gained access to the drug through its $4.3bn acquisition of CymaBay in March

- PMLiVE

New phase 2 study launched to evaluate triple drug combination in pancreatic cancer

The PRIMUS-006 study will evaluate Lilly/Genentech’s Gemzar in combination with Merck’s Keytruda and Immodulon’s IMM-101

- PMLiVE

Ipsen’s Onivyde regimen granted FDA approval to treat pancreatic cancer

Around 60,000 people are diagnosed with pancreatic adenocarcinoma in the US every year

- PMLiVE

FDA grants fast track designation to Candel’s immunotherapy in pancreatic cancer

The disease is the fourth leading cause of cancer-related death in the US, accounting for 3.3% of new cancer cases

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links